Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial - Journal of Cystic Fibrosis. Fig. 1 Study design (A) and disposition (B).
Fig. 2 Overall efficacy: A) relative change in FEV1% predicted from baseline over three cycles (efficacy population); and B) change from baseline in Pseudomonas aeruginosa sputum density (efficacy population). Background. CF Centres. Lumacaftor/ivacaftor combination therapy. Nebulised Levofloxacin (Quinsair tm) Drug Development Pipeline. Orkambi, INN-lumacaftor & ivacaftor. Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study. + Author Affiliations Correspondence to Dr Antje Schuster, Zentrum für Kinder und Jugendmedizin, Moorenstrasse 5, Düsseldorf 40225, Germany;email@example.com Received 17 April 2012 Accepted 11 October 2012 Published Online First 7 November 2012 Abstract Purpose To assess efficacy and safety of a new dry powder formulation of inhaled colistimethate sodium in patients with cystic fibrosis (CF) aged ≥6 years with chronic Pseudomonas aeruginosa lung infection.
Study design and methods A prospective, centrally randomised, phase III, open-label study in patients with stable CF aged ≥6 years with chronic P aeruginosa lung infection. Patients were randomised to Colobreathe dry powder for inhalation (CDPI, one capsule containing colistimethate sodium 1 662 500 IU, twice daily) or three 28-day cycles with twice-daily 300 mg/5 ml tobramycin inhaler solution (TIS). Results 380 patients were randomised.
Trial Reg No EudraCT 2004-003675-36. Key messages What is the key question? Figure 1. Clinical Review : Cystic fibrosis. 798. 871. 1302. Asthma, COPD, and Asthma-COPD Overlap Syndrome - Global Initiative for Chronic Obstructive Lung Disease - GOLD. GOLD documents are protected by copyright.
A single copy of this document may be downloaded for your own educational use, but copies may not be made for distribution or posted on a website without authorization from GOLD. A significant proportion of adult patients over age 40 who present with symptoms of a chronic airways disease have features of both asthma and COPD. Several diagnostic terms, most including the word ‘overlap’, have been applied to such patients, and the topic has been extensively reviewed. However, there is no generally agreed term or defining features for this category of chronic airflow limitation, although a definition based upon consensus has been published for overlap in patients with existing COPD. This document has been developed by the Science Committees of both GINA and GOLD, based on a detailed review of available literature and consensus.
Global Initiative for Chronic Obstructive Lung Disease - Global Initiative for Chronic Obstructive Lung Disease - GOLD. Inhaler Technique Videos. (*NEW) 2016 Pocket Guide for Asthma Management and Prevention - Global Initiative for Asthma - GINA. Factors that may trigger or worsen asthma symptoms include viral infections, domestic or occupational allergens (e.g., house dust mite, pollens, cockroach), tobacco smoke, exercise and stress.
These responses are more likely when asthma is uncontrolled. Some drugs can induce or trigger asthma, e.g., beta-blockers, and (in some patients) aspirin or other NSAIDs. Asthma flare-ups (also called exacerbations or attacks) may occur, even in people taking asthma treatment. When asthma is uncontrolled, or in some high-risk patients, these episodes are more frequent and more severe, and may be fatal. A stepwise approach to treatment takes into account the effectiveness of available medications, their safety, and their cost to the payer or patient. Regular controller treatment, particularly with inhaled corticosteroid (ICS)-containing medications, markedly reduces the frequency and severity of asthma symptoms and the risk of having a flare-up.
BTS/SIGN British guideline on the management of asthma. Cystic Fibrosis Therapeutics: The Road Ahead. Ahead of the Curve Seattle Children's Hospital and the University of Washington School of Medicine, Seattle, WA Received 29 June 2012, Accepted 6 July 2012, Available online 16 December 2015 Choose an option to locate/access this article: Check if you have access through your login credentials or your institution Check access Get rights and content A great deal of excitement and hope has followed the successful trials and US Food and Drug Administration approval of the drug ivacaftor (Kalydeco), the first therapy available that targets the underlying defect that causes cystic fibrosis (CF).
New pharmacological approaches for cystic fibrosis: Promises, progress, pitfalls. Associate editor: P.
Molenaar a Department of Thoracic Medicine, Prince Charles Hospital, Brisbane, Australiab Queensland Children's Medical Research Institute, Brisbane, Australiac Pediatric Pulmonology, Department of Pediatrics, University of Leuven, Leuven, Belgiumd University of Lisboa, Faculty of Sciences, BioFIG — Centre for Biodiversity, Functional and Integrative Genomics, Campo Grande, C8 bdg, 1749-016 Lisboa, Portugal Available online 14 June 2014 Choose an option to locate/access this article: Check if you have access through your login credentials or your institution Check access Get rights and content Abstract With the discovery of the CFTR gene in 1989, the search for therapies to improve the basic defects of cystic fibrosis (CF) commenced.
Keywords Cystic fibrosis; Cystic fibrosis transmembrane conductance regulator protein; CFTR2; Correctors; Potentiators; Trial end-points.